Fig. 1
From: CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress
Recombinant purified ALK4L75A-Fc inhibits CRIPTO-dependent tumor cell growth in vitro and in vivo. a Confluency of NCCIT cells grown in vitro for 6 days in the presence (10 μg/ml) or absence of purified recombinant ALK4L75A-Fc. Standard deviation across triplicates is shown. b Effect of rmCRIPTO on the growth inhibitory effect of ALK4L75A-Fc in NCCIT cell cultures. Standard deviation across triplicates is shown. c Representative immunofluorescent anti-human IgG staining of tumor tissue from mice bearing NCCIT xenografts that were treated with ALK4L75A-Fc (5 mg/kg, I.P.) or vehicle (inset). A, acellular region; V, presumptive vasculature. Scale bar = 100 μm. d, e Effect of ALK4L75A-Fc injection compared to saline on growth of NCCIT xenografted tumors at the indicated doses and over the indicated time periods